IL2 and neoplasm: While DCs/tumor fusions approach has been developed in animal studies, many adjuvants, including IL-2, IL-12, IL-18, and synthetic oligodeoxynucleotides (ODNs) containing specific bacterial unmethylated CpG motifs (CpG ODNs), have been used to enhance the ability of DC/tumor fusion vaccines to evoke antitumor immune responses [26, 29, 31, 54, 61].